CompletedNot Applicable

Prediction of Upgrade to Invasive Cancer in Patients Diagnosed With Ductal Carcinoma in Situ by Percutaneous Core Needle Biopsy

South Korea113 participantsStarted 2020-07-13

Plain-language summary

It is considered that whether or not the accompanying invasive cancer classified through MRI images of breast cancer patients identified as Ductal Carcinoma in situ (DCIS) through preoperative tissue biopsy is significantly consistent with the postoperative stage. Therefore, this study intend to evaluate the effectiveness as a diagnostic tool that can help determine the axillary lymph node surgery by predicting the possibility of post-operative up-staging using magnetic resonance imagings of breast cancer patients who have been identified as ductal carcinoma in situ and are scheduled for surgery.

Who can participate

Age range19 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult over 19 years-old * Breast Ductal Carcinoma in-situ patients who diagnosed preoperative tissue biopsy * A person who understands this study and agrees with willingness to participate Exclusion Criteria: * Ductal Carcinoma in-situ which diagnosed excisional biopsy * When there is no lesion that can be discriminated from magnetic resonance imaging * Neoadjuvant chemotherapy patients * Patients who have complication (hematoma, abscess etc.) after preoperative biopsy

What they're measuring

Comparing of Preoperative MRI and Postoperative histopathologic results

Timeframe: 2 weeks after surgery

Trial details

NCT IDNCT04498611

SponsorSeoul National University Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-04-30

View on ClinicalTrials.gov More Carcinoma, Ductal, Breast trials